Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature.
- Author:
Hye Won LEE
1
;
Moon Jae CHUNG
;
Huapyong KANG
;
Heun CHOI
;
Youn Jeong CHOI
;
Kyung Joo LEE
;
Seung Woo LEE
;
Seung Hyuk HAN
;
Jin Seok KIM
;
Si Young SONG
Author Information
1. Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. mjchung@yuhs.ac
- Publication Type:Case Reports ; Review
- Keywords:
Hemolytic-uremic syndrome;
Gemcitabine;
Pancreatic neoplasms
- MeSH:
Antimetabolites, Antineoplastic/*adverse effects;
Deoxycytidine/adverse effects/*analogs & derivatives;
Hemolytic-Uremic Syndrome/*chemically induced;
Humans;
Male;
Middle Aged;
Pancreatic Neoplasms/*drug therapy;
Treatment Outcome
- From:Gut and Liver
2014;8(1):109-112
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomycin, cisplatin, and most recently, gemcitabine. The outcome of gemcitabine-induced HUS is poor, and the disease has a high mortality rate. This study reports a case of gemcitabine-induced HUS in a patient with pancreatic cancer in Korea.
